Bioinformatics Strategies to Identify Shared Molecular Biomarkers That Link Ischemic Stroke and Moyamoya Disease with Glioblastoma.
Md Khairul IslamMd Rakibul IslamMd Habibur RahmanMd Zahidul IslamMd Al AminKazi Rejvee AhmedMd Ataur RahmanMohammad Ali MoniBonlgee KimPublished in: Pharmaceutics (2022)
Expanding data suggest that glioblastoma is accountable for the growing prevalence of various forms of stroke formation, such as ischemic stroke and moyamoya disease. However, the underlying deterministic details are still unspecified. Bioinformatics approaches are designed to investigate the relationships between two pathogens as well as fill this study void. Glioblastoma is a form of cancer that typically occurs in the brain or spinal cord and is highly destructive. A stroke occurs when a brain region starts to lose blood circulation and prevents functioning. Moyamoya disorder is a recurrent and recurring arterial disorder of the brain. To begin, adequate gene expression datasets on glioblastoma, ischemic stroke, and moyamoya disease were gathered from various repositories. Then, the association between glioblastoma, ischemic stroke, and moyamoya was established using the existing pipelines. The framework was developed as a generalized workflow to allow for the aggregation of transcriptomic gene expression across specific tissue; Gene Ontology (GO) and biological pathway, as well as the validation of such data, are carried out using enrichment studies such as protein-protein interaction and gold benchmark databases. The results contribute to a more profound knowledge of the disease mechanisms and unveil the projected correlations among the diseases.
Keyphrases
- gene expression
- atrial fibrillation
- middle cerebral artery
- spinal cord
- protein protein
- white matter
- electronic health record
- dna methylation
- cerebral ischemia
- risk factors
- papillary thyroid
- spinal cord injury
- climate change
- neuropathic pain
- rna seq
- single cell
- mouse model
- genome wide
- autism spectrum disorder
- squamous cell
- multidrug resistant
- transcription factor